References

pulmo

Пульмонология

PULMONOLOGIYA

0869-01892541-9617

Scientific and Practical Journal “PULMONOLOGIYA” LLC

10.18093/0869-0189-2011-0-3-9-52

pulmo-329

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL GUIDELINES

Лечение грибковой инфекции у взрослых пациентов в пульмонологической практике и интенсивной терапии

Treatment of fungal infections in adult pulmonary and critical care patients

Лимпер

Э. Х.

Limper

A. H.

Нокс

К. С.

Knox

K. S.

Сарози

Дж. А.

Sarosi

G. A.

Ампель

Н. М.

Ampel

N. M.

Беннетт

Дж. Е.

Bennett

J. E.

Катанзаро

А.

Catanzaro

A.C

Давьес

С. Ф.

Davies

S. F.

Дисмукс

В. Е.

Dismukes

W. E.

Хейг

Ч. А.

Hage

C. A.

Марр

К. А.

Marr

K. A.

Моди

К. Х.

Mody

C. H.

Перфект

Дж. Р.

Perfect

J. R.

Стивенс

Д. А.

Stevens

D. A.

2011

28062011

03952

2011

Лимпер Э.Х., Нокс К.С., Сарози Д.А., Ампель Н.М., Беннетт Д.Е., Катанзаро А., Давьес С.Ф., Дисмукс В.Е., Хейг Ч.А., Марр К.А., Моди К.Х., Перфект Д.Р., Стивенс Д.А.

Limper A.H., Knox K.S., Sarosi G.A., Ampel N.M., Bennett J.E., Catanzaro A., Davies S.F., Dismukes W.E., Hage C.A., Marr K.A., Mody C.H., Perfect J.R., Stevens D.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.pulmonology.ru/pulm/article/view/329

Источник: A.H.Limper, K.S.Knox, G.A.Sarosi et al. Official American Thoracic Society Statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am. J. Respir. Crit. Care Med. 2011; 183: 96–128.

References1

McGowan J.E. Jr., Chesney P.J., Crossley K.B., LaForce F.M. Guidelines for the use of systemic glucocorticosteroids in the management of selected infections. Working group on steroid use, antimicrobial agents committee, Infectious Diseases Society of America. J. Infect. Dis. 1992; 165: 1–13.

Sobel J.D. Practice guidelines for the treatment of fungal infections. For the mycoses study group, Infectious Diseases Society of America.Clin. Infect. Dis. 2000; 30: 652.

Schunemann H.J., Jaeschke R., Cook D.J. et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ats guidelines and recommendations. Am. J. Respir. Crit. Care Med. 2006; 174: 605–614.

Schunemann H.J., Osborne M., Moss J. et al. An official American Thoracic Society policy statement: managing conflict of interest in professional societies. Am. J. Respir. Crit. Care Med 2009; 180: 564–580.

Barcia J.P. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B. Pharmacotherapy 1998; 18: 874–876.

Wright D.G., Robichaud K.J., Pizzo P.A., Deisseroth A.B. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N. Engl. J. Med 1981; 304: 1185–1189.

Goren M.P., Viar M.J., Shenep J.L. et al. Monitoring serum aminoglycoside concentrations in children with amphotericin B nephrotoxicity. Pediatr. Infect. Dis. J. 1988; 7: 698–703.

Mayer J., Doubek M., Doubek J. et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J. Infect. Dis. 2002; 186: 379–388.

Nivoix Y., Ubeaud5Sequier G., Engel P. et al. Drugdrug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr. Drug Metab. 2009; 10: 395–409.

Willems L., van der Geest R., de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J. Clin. Pharm. Ther. 2001; 26: 159–169.

Stevens D.A. Ketoconazole metamorphosis: an antimicrobial becomes an endocrine drug. Arch. Intern. Med. 1985; 145: 813–815.

Zonios D.I., Bennett J.E. Update on azole antifungals. Semin. Respir. Crit. Care Med. 2008; 29: 198–210.

Stevens D.A. Itraconazole in cyclodextrin solution. Pharmacotherapy 1999; 19: 603–611.

Toon S., Ross C.E., Gokal R., Rowland M. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br. J. Clin. Pharmacol. 1990; 29: 221–226.

Pascual A., Calandra T., Bolay S. et al. Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 2008; 46: 201–211.

Schwartz S., Milatovic D., Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br. J. Haematol. 1997; 97: 663–665.

Walsh T.J., Raad I., Patterson T.F. et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 2007; 44: 2–12.

Stevens D.A., Rendon A., Gaona5Flores V. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007; 132: 952–958.

Ullmann A.J., Cornely O.A. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr. Opin. Infect. Dis. 2006; 19: 571–576.

Raad I.I., Graybill J.R., Bustamante A.B. et al. Safety of longterm oral posaconazole use in the treatment of refractory invasive fungal infections. Clin. Infect. Dis. 2006; 42: 1726–1734.

Powles M.A., Liberator P., Anderson J. et al. Efficacy of MK-991 (l-743, 872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob. Agents Chemother. 1998; 42: 1985–1989.

Kottom T.J., Limper A.H. Cell wall assembly by Pneumocystis carinii: evidence for a unique gsc-1 subunit mediating beta-1,3-glucan deposition. J. Biol. Chem. 2000; 275: 40628–40634.

Joseph J.M., Jain R., Danziger L.H. Micafungin: a new echinocandin antifungal. Pharmacotherapy 2007; 27: 53–67.

Croft D.R., Trapp J., Kernstine K. et al. Fdg-pet imagingand the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer 2002; 36: 297–301.

Olson E.J., Utz J.P., Prakash U.B. Therapeutic bronchoscopy in broncholithiasis. Am. J. Respir. Crit. Care Med. 1999; 160: 766–770.

Menivale F., Deslee G., Vallerand H. et al. Therapeutic management of broncholithiasis. Ann. Thorac. Surg. 2005; 79: 1774–1776.

Loyd J.E., Tillman B.F., Atkinson J.B., Des Prez R.M. Mediastinal fibrosis complicating histoplasmosis. Medicine (Baltimore) 1988; 67: 295–310.

Hackstein N., Fegbeutel C., Rau W.S. Idiopathic mediastinal fibrosis as differential diagnosis of mediastinal structures. Rofo 2004; 176: 1510–1511.

Savelli B.A., Parshley M., Morganroth M.L. Successful treatment of sclerosing cervicitis and fibrosing mediastinitis with tamoxifen. Chest 1997; 111: 1137–1140.

Doyle T.P., Loyd J.E., Robbins I.M. Percutaneous pulmonary artery and vein stenting: a novel treatment for mediastinal fibrosis. Am. J. Respir. Crit. Care Med. 2001; 164: 657–660.

Manali E.D., Saad C.P., Krizmanich G., Mehta A.C. Endobronchial findings of fibrosing mediastinitis. Respir. Care 2003; 48: 1038–1042.

Brodsky A.L., Gregg M.B., Loewenstein M.S. et al. Outbreak of histoplasmosis associated with the 1970 Earth Day activities. Am. J. Med. 1973; 54: 333–342.

Johnson P.C., Wheat L.J., Cloud G.A. et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann. Intern. Med. 2002; 137: 105–109.

Wheat J., Hafner R., Korzun A.H. et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome: AIDS clinical trial group. Am. J. Med. 1995; 98: 336–342.

Wheat J., Hafner R., Wulfsohn M. et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 1993; 118: 610–616.

Goldman M., Zackin R., Fichtenbaum C.J. et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin. Infect. Dis. 2004; 38: 1485–1489.

Breton G., Adle5Biassette H., Therby A. et al. Immune reconstitution inflammatory syndrome in hiv-infected patients with disseminated histoplasmosis. AIDS 2006; 20: 119–121.

McKinsey D.S., Wheat L.J., Cloud G.A. et al. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. Clin. Infect. Dis. 1999; 28: 1049–1056.

Wood K.L., Hage C.A., Knox K.S. et al. Histoplasmosis after treatment with antitumor necrosis factor-alpha therapy. Am. J. Respir. Crit. Care Med. 2003; 167: 1279–1282.

Goodwin R.A. Jr, Shapiro J.L., Thurman G.H. et al. Disseminated histoplasmosis: clinical and pathologic correlations. Medicine (Baltimore) 1980; 59: 1–33.

Parker J.D., Sarosi G.A., Doto I.L. et al. Treatment of chronic pulmonary histoplasmosis. N. Engl. J. Med 1970; 283: 225–229.

Kennedy C.C., Limper A.H. Redefining the clinical spectrum of chronic pulmonary histoplasmosis: a retrospective case series of 46 patients. Medicine (Baltimore) 2007; 86: 252–258.

Dismukes W.E., Bradsher R.W. Jr, Cloud G.C. et al. Itraconazole therapy for blastomycosis and histoplasmosis: Niaid mycoses study group. Am. J. Med. 1992; 93: 489–497.

Perfect J.R., Marr K.A., Walsh T.J. et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 2003; 36: 1122–1131.

Restrepo A., Tobon A., Clark B. et al. Salvage treatment of histoplasmosis with posaconazole. J. Infect. 2007; 54: 319–327.

Li R.K., Ciblak M.A., Nordoff N. et al. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob. Agents Chemother. 2000; 44: 1734–1736.

Connolly P., Wheat J., Schnizlein5Bick C. et al. Comparison of a new triazole antifungal agent, schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob. Agents Chemother. 1999; 43: 322–328.

Clark B., Foster R., Tunbridge A., Green S. A. Case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole. J. Infect. 2005; 51: e177–e180.

Kohler S., Wheat L.J., Connolly P. et al. Comparison of the echinocandin caspofungin with amphotericin b for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob. Agents Chemother. 2000; 44: 1850–1854.

Dall L., Salzman G. Treatment of pulmonary sporotrichosis with ketoconazole. Rev. Infect. Dis. 1987; 9: 795–798.

Mercurio M.G., Elewski B.E. Therapy of sporotrichosis. Semin. Dermatol. 1993; 12: 285–289.

Kauffman C.A. Old and new therapies for sporotrichosis. Clin. Infect. Dis. 1995; 21: 981–985.

Sharkey5Mathis P.K., Kauffman C.A., Graybill J.R. et al. Treatment of sporotrichosis with itraconazole: Niaid mycoses study group. Am. J. Med. 1993; 95: 279–285.

Lemos L.B., Baliga M., Guo M. Acute respiratory distress syndrome and blastomycosis: presentation of nine cases and review of the literature. Ann. Diagn. Pathol. 2001; 5: 1–9.

Sarosi G.A., Davies S.F. Blastomycosis. Am. Rev. Respir. Dis. 1979; 120: 911–938.

Pappas P.G., Pottage J.C., Powderly W.G. et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 1992; 116: 847–853.

Pappas P.G., Threlkeld M.G., Bedsole G.D. et al. Blastomycosis in immunocompromised patients. Medicine (Baltimore) 1993; 72: 311–325.

Chapman S.W., Bradsher R.W. Jr, Campbell G.D. Jr et al. Practice guidelines for the management of patients with blastomycosis: Infectious Diseases Society of America. Clin. Infect. Dis. 2000; 30: 679–683.

Saiz P., Gitelis S., Virkus W. et al. Blastomycosis of long bones. Clin. Orthop. Relat. Res. 2004; 255–259.

Wiesman I.M., Podbielski F.J., Hernan M.J. et al. Thoracic blastomycosis and empyema. JSLS 1999; 3: 75–78.

Hadjipavlou A.G., Mader J.T., Nauta H.J. et al. Blastomycosis of the lumbar spine: case report and review of the literature, with emphasis on diagnostic laboratory tools and management. Eur. Spine. J. 1998; 7: 416–421.

Saccente M., Abernathy R.S., Pappas P.G. et al. Vertebral blastomycosis with paravertebral abscess: report of eight cases and review of the literature. Clin. Infect. Dis. 1998; 26: 413–418.

Bradsher R.W. Therapy of blastomycosis. Semin. Respir. Infect. 1997; 12: 263–267.

Ralph E.D., Plaxton W.R., Sharpe M.D. Treatment of severe pulmonary blastomycosis with oral itraconazole: case report. Clin. Infect. Dis. 1999; 29: 1336–1337.

Parker J.D., Doto I.L., Tosh F.E. A decade of experience with blastomycosis and its treatment with amphotericin B: a national communicable disease center cooperative mycoses study. Am. Rev. Respir. Dis. 1969; 99: 895–902.

Chowfin A., Tight R., Mitchell S. Recurrent blastomycosis of the central nervous system: case report and review. Clin. Infect. Dis. 2000; 30: 969–971.

Cook P.P. Amphotericin B. lipid complex for the treatment of recurrent blastomycosis of the brain in a patient previously treated with itraconazole. South Med. J. 2001; 94: 548–549.

Pappas P.G., Bradsher R.W., Kauffman C.A. et al. Treatment of blastomycosis with higher doses of fluconazole: the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin. Infect. Dis. 1997; 25: 200–205.

Pappas P.G., Bradsher R.W., Chapman S.W. et al. Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin. Infect. Dis. 1995; 20: 267–271.

Sorensen K.N., Clemons K.V., Stevens D.A. Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis. Mycopathologia 1999; 146: 53–65.

Sugar A.M., Liu X.P. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob. Agents Chemother. 2001; 45: 601–604.

Bakleh M., Aksamit A.J., Tleyjeh I.M., Marshall W.F. Successful treatment of cerebral blastomycosis with voriconazole. Clin. Infect. Dis. 2005; 40: e69–e71.

Borgia S.M., Fuller J.D., Sarabia A., El5Helou P. Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen. Med. Mycol. 2006; 44: 659–664.

Morgan D., Young R.F., Chow A.W. et al. Recurrent intracerebral blastomycotic granuloma: diagnosis and treatment. Neurosurgery 1979; 4: 319–324.

Lahm T., Neese S., Thornburg A.T. et al. Corticosteroids for blastomycosis-induced ARDS: a report of two patients and review of the literature. Chest 2008; 133: 1478–1480.

Schwarz E.B., Postlethwaite D.A., Hung Y.Y., Armstrong M.A. Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women. Ann. Intern. Med. 2007; 147: 370–376.

Chandrasekar P.H. Increased dose of echinocandins for invasive fungal infections: bonanza for the patient or the pharmaceutical industry? Bone Marrow. Transplant. 2007; 39: 129–131.

Galgiani J.N., Ampel N.M., Blair J.E. et al. Coccidioidomycosis. Clin. Infect. Dis. 2005; 41: 1217–1223.

Valdivia L., Nix D., Wright M. et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg. Infect. Dis. 2006; 12: 958–962.

Galgiani J.N., Ampel N.M., Catanzaro A. et al. Practice guideline for the treatment of coccidioidomycosis: Infectious Diseases Society of America. Clin. Infect. Dis. 2000; 30: 658–661.

Bergstrom L., Yocum D.E., Ampel N.M. et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthr. and Rheum. 2004; 50: 1959–1966.

Ampel N.M., Wieden M.A., Galgiani J.N. Coccidioidomycosis: clinical update. Rev. Infect. Dis. 1989; 11: 897–911.

Gifford M.A., Buss W.C., Douds R.J. Data on coccidioides fungus infection, Kern county, 1901–1936. in: Annual report Kern County Health Department for the fiscal year July 1, 1936, to June 30, 1937. Bakersfield, CA; 1937. 39–54.

Dewsnup D.H., Galgiani J.N., Graybill J.R. et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann. Intern. Med. 1996; 124: 305–310.

Stevens D.A., Shatsky S.A. Intrathecal amphotericin in the management of coccidioidal meningitis. Semin. Respir. Infect. 2001; 16: 263–269.

Catanzaro A., Fierer J., Friedman P.J. Fluconazole in the treatment of persistent coccidioidomycosis. Chest 1990; 97: 666–669.

Galgiani J.N., Catanzaro A., Cloud G.A. et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: a randomized, double-blind trial. Mycoses Study Group. Ann. Intern. Med. 2000; 133: 676–686.

Graybill J.R., Stevens D.A., Galgiani J.N. et al. Itraconazole treatment of coccidioidomycosis: Naiad Mycoses Study Group. Am. J. Med. 1990; 89: 282–290.

Anstead G.M., Corcoran G., Lewis J. et al. Refractory coccidioidomycosis treated with posaconazole. Clin. Infect. Dis. 2005; 40: 1770–1776.

Cortez K.J., Walsh T.J., Bennett J.E. Successful treatment of coccidioidal meningitis with voriconazole. Clin. Infect. Dis. 2003; 36: 1619–1622.

Prabhu R.M., Bonnell M., Currier B.L., Orenstein R. Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole. Clin. Infect. Dis. 2004; 39: e74–e77.

Shikanai5Yasuda M.A., Benard G., Higaki Y. et al. Randomized trial with itraconazole, ketoconazole and sulfadiazine in paracoccidioidomycosis. Med. Mycol. 2002; 40: 411–417.

Queiroz5Telles F., Goldani L.Z., Schlamm H.T. et al. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis 2007; 45: 1462–1469. Am. Thorac. Soc. Doc. 123.

Byrnes E.J. III, Bildfell R.J., Frank S.A. et al. Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific northwest in the United States. J. Infect. Dis. 2009; 199: 1081–1086.

Granger D.L., Perfect J.R., Durack D.T. Virulence of Cryptococcus neoformans: regulation of capsule synthesis by carbon dioxide. J. Clin. Invest. 1985; 76: 508–516.

Chaskes S., Frases S., Cammer M. et al. Growth and pigment production on d-tryptophan medium by Cryptococcus gattii, Cryptococcus neoformans, and Candida albicans. J. Clin. Microbiol. 2008; 46: 255–264.

Hoang L.M., Maguire J.A., Doyle P. et al. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997–2002): epidemiology, microbiology and histopathology. J. Med. Microbiol. 2004; 53: 935–940.

Kidd S.E., Hagen F., Tscharke R.L. et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc. Natl. Acad. Sci. USA 2004; 101: 17258–17263.

Rozenbaum R., Goncalves A.J. Clinical epidemiological study of 171 cases of cryptococcosis. Clin. Infect. Dis. 1994; 18: 369–380.

100

Aberg J.A., Mundy L.M., Powderly W.G. Pulmonary cryptococcosis in patients without HIV infection. Chest 1999; 115: 734–740.

101

Zlupko G.M., Fochler F.J., Goldschmidt Z.H. Pulmonary cryptococcosis presenting with multiple pulmonary nodules. Chest 1980; 77: 575.

102

Khoury M.B., Godwin J.D., Ravin C.E. et al. Thoracic cryptococcosis: immunologic competence and radiologic appearance. Am. J. Roentgenol. 1984; 142: 893–896.

103

Penmetsa S., Rose T.A., Crook E.D. Rapid respiratory deterioration and sudden death due to disseminated cryptococcosis in a patient with the acquired immunodeficiency syndrome. South. Med. J. 1999; 92: 927–929.

104

Nadrous H.F., Antonios V.S., Terrell C.L., Ryu J.H. Pulmonary cryptococcosis in nonimmunocompromised patients. Chest 2003; 124: 2143–2147.

105

Vilchez R.A., Linden P., Lacomis J., Costello P. et al. Acute respiratory failure associated with pulmonary cryptococcosis in non-AIDS patients. Chest 2001; 119: 1865–1869.

106

Pappas P.G., Perfect J.R., Cloud G.A. et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin. Infect. Dis. 2001; 33: 690–699.

107

Dromer F., Mathoulin S., Dupont B. et al. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virusnegative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. Clin. Infect. Dis. 1996; 22: S154–S160.

108

Gomez5Lopez A., Zaragoza O., Dos Anjos Martins M. et al. In vitro susceptibility of Cryptococcus gattii clinical isolates. Clin. Microbiol. Infect. 2008; 14: 727–730.

109

Majid A.A. Surgical resection of pulmonary cryptococcomas in the presence of cryptococcal meningitis. J. Roy. Coll. Surg. Edinb. 1989; 34: 332–333.

110

Smith F.S., Gibson P., Nicholls T.T., Simpson J.A. Pulmonary resection for localized lesions of cryptococcosis (torulosis): a review of eight cases. Thorax 1976; 31: 121–126.

111

Vilchez R.A., Irish W., Lacomis J. et al. The clinical epidemiology of pulmonary cryptococcosis in non-AIDS patients at a tertiary care medical center. Medicine (Baltimore) 2001; 80: 308–312.

112

Mody C.H., Toews G.B., Lipscomb M.F. Cyclosporin a inhibits the growth of Cryptococcus neoformans in a murine model. Infect. and Immun. 1988; 56:7–12.

113

Mody C.H., Toews G.B., Lipscomb M.F. Treatment of murine cryptococcosis with cyclosporin-a in normal and athymic mice. Am. Rev. Respir. Dis. 1989; 139: 8–13.

114

Blankenship J.R., Singh N., Alexander B.D., Heitman J. Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens. J. Clin. Microbiol. 2005; 43: 464–467.

115

Hage C.A., Wood K.L., Winer5Muram H.T. et al. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factoralpha therapy. Chest 2003; 124: 2395–2397.

116

Shrestha R.K., Stoller J.K., Honari G. et al. Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel. Respir. Care 2004; 49: 606–608.

117

Arend S.M., Kuijper E.J., Allaart C.F. et al. Cavitating pneumonia after treatment with infliximab and prednisone. Eur. J. Clin. Microbiol. Infect. Dis. 2004; 23: 638–641.

118

Nath D.S., Kandaswamy R., Gruessner R. et al. Fungal infections in transplant recipients receiving alemtuzumab. Transplant. Proc. 2005; 37: 934–936.

119

Sider L., Westcott M.A. Pulmonary manifestations of cryptococcosis in patients with AIDS: CT features. J. Thorac. Imag. 1994; 9: 78–84.

120

Cameron M.L., Bartlett J.A., Gallis H.A., Waskin H.A. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev. Infect. Dis. 1991; 13: 64–67.

121

Zinck S.E., Leung A.N., Frost M. et al. Pulmonary cryptococcosis: CT and pathologic findings. J. Comput. Assist. Tomogr. 2002; 26: 330–334.

122

van der Horst C.M., Saag M.S., Cloud G.A. et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome: National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N. Engl. J. Med. 1997; 337: 15–21.

123

Denning D.W., Tucker R.M., Hanson L.H. et al. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch. Intern. Med. 1989; 149: 2301–2308.

124

de Gans J., Portegies P., Tiessens G. et al. Itraconazole compared with amphotericin B plus flucytosine in aids patients with cryptococcal meningitis. AIDS 1992; 6: 185–190.

125

Bennett J.E., Dismukes W.E., Duma R.J. et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N. Engl. J. Med 1979; 301: 126–131.

126

Dismukes W.E., Cloud G., Gallis H.A. et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N. Engl. J. Med. 1987; 317: 334–341.

127

White M., Cirrincione C., Blevins A., Armstrong D. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J. Infect. Dis. 1992; 165: 960–963.

128

Saag M.S., Powderly W.G., Cloud G.A. et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis: the Niaid Mycoses Study Group and the AIDS Clinical Trials Group. N. Engl. J. Med. 1992; 326: 83–89.

129

Bicanic T., Wood R., Meintjes G. et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin. Infect. Dis. 2008; 47: 123–130.

130

Larsen R.A., Bauer M., Thomas A.M., Graybill J.R. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. Antimicrob. Agents. Chemother. 2004; 48: 985–991.

131

Brouwer A.E., Rajanuwong A., Chierakul W. et al. Combination antifungal therapies for HIVassociated cryptococcal meningitis: a randomised trial. Lancet 2004; 363: 1764–1767.

132

Coker R.J., Viviani M., Gazzard B.G. et al. Treatment of cryptococcosis with liposomal amphotericin B (ambisome) in 23 patients with AIDS. AIDS 1993; 7: 829–835.

133

Leenders A.C., Reiss P., Portegies P. et al. Liposomal amphotericin B (ambisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997; 11: 1463–1471.

134

Diamond D.M., Bauer M., Daniel B.E. et al. Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. Antimicrob. Agents Chemother. 1998; 42: 528–533.

135

Bozzette S.A., Larsen R.A., Chiu J. et al. A placebocontrolled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome: California Collaborative Treatment Group. N. Engl. J. Med. 1991; 324: 580–584.

136

Saag M.S., Cloud G.A., Graybill J.R. et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis: National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin. Infect. Dis. 1999; 28: 291–296.

137

Powderly W.G., Saag M.S., Cloud G.A. et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome: The Niaid AIDS Clinical Trials Group and Mycoses Study Group. N. Engl. J. Med. 1992; 326: 793–798.

138

Alves S.H., Lopes J.O., Costa J.M., Klock C. Development of secondary resistance to fluconazole in Cryptococcus neoformans isolated from a patient with AIDS. Rev. Inst. Med. Trop. Sao Paulo 1997; 39: 359–361.

139

Armengou A., Porcar C., Mascaro J., Garcia5Bragado F. Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 1996; 23: 1337–1338.

140

Birley H.D., Johnson E.M., McDonald P. et al. Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis. Int. J. STD AIDS 1995; 6: 353–355.

141

Friese G., Discher T., Fussle R. et al. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease. AIDS 2001; 15: 2344–2345.

142

King M.D., Perlino C.A., Cinnamon J., Jernigan J.A. Paradoxical recurrent meningitis following therapy of cryptococcal meningitis: an immune reconstitution syndrome after initiation of highly active antiretroviral therapy. Int. J. STD AIDS 2002; 13: 724–726.

143

Jenny5Avital E.R., Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin. Infect. Dis. 2002; 35: e128–e133.

144

Shelburne S.A. III, Darcourt J., White A.C. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 2005; 40: 1049–1052.

145

Mussini C., Pezzotti P., Miro J.M. et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin. Infect. Dis. 2004; 38: 565–571.

146

Vibhagool A., Sungkanuparph S., Mootsikapun P. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin. Infect. Dis. 2003; 36: 1329–1331.

147

Rambeloarisoa J., Batisse D., Thiebaut J.B. et al. Intramedullary abscess resulting from disseminated cryptococcosis despite immune restoration in a patient with AIDS. J. Infect. 2002; 44: 185–188.

148

Breton G., Seilhean D., Cherin P. et al. Paradoxical intracranial cryptococcoma in a human immunodeficiency virusinfected man being treated with combination antiretroviral therapy. Am. J. Med. 2002; 113: 155–157.

149

Krishnarao T.V., Galgiani J.N. Comparison of the in vitro activities of the echinocandin ly303366, the pneumocandin mk-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 1997; 41: 1957–1960.

150

Feldmesser M., Kress Y., Mednick A., Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J. Infect. Dis. 2000; 182: 1791–1795.

151

Brummer E., Kamei K., Miyaji M. Anticryptococcal activity of voriconazole against Cryptococcus neoformans var. gatti vs var. neoformans: comparison with fluconazole and effect of human serum. Mycopathologia 1998; 142: 3–7.

152

Sabatelli F., Patel R., Mann P.A. et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 2006; 50: 2009–2015.

153

Sabbatani S., Manfredi R., Pavoni M. et al. Voriconazole proves effective in long-term treatment of a cerebral cryptococcoma in a chronic nephropathic hiv-negative patient, after fluconazole failure. Mycopathologia 2004; 158: 165–171.

154

Pappas P.G., Bustamante B., Ticona E. et al. Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J. Infect. Dis. 2004; 189: 2185–2191.

155

Fessler R.D., Sobel J., Guyot L. et al. Management of elevated intracranial pressure in patients with cryptococcal meningitis. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1998; 17: 137–142.

156

Graybill J.R., Sobel J., Saag M. et al. Diagnosis and management of increased intracranial pressure in patients with aids and cryptococcal meningitis: the Niaid Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin. Infect. Dis. 2000; 30: 47–54.

157

Johnston S.R., Corbett E.L., Foster O. et al. Raised intracranial pressure and visual complications in AIDS patients with cryptococcal meningitis. J. Infect. 1992; 24: 185–189.

158

Liliang P.C., Liang C.L., Chang W.N. et al. Shunt surgery for hydrocephalus complicating cryptococcal meningitis in human immunodeficiency virus-negative patients. Clin.Infect. Dis. 2003; 37: 673–678.

159

Liliang P.C., Liang C.L., Chang W.N. et al. Use of ventriculoperitoneal shunts to treat uncontrollable intracranial hypertension in patients who have cryptococcal meningitis without hydrocephalus. Clin. Infect. Dis. 2002; 34: E64–E68.

160

Park M.K., Hospenthal D.R., Bennett J.E. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin. Infect. Dis. 1999; 28: 629–633.

161

Macsween K.F., Bicanic T., Brouwer A.E. et al. Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review. J. Infect. 2005; 51: e221–e224.

162

Manosuthi W., Sungkanuparph S., Chottanapund S. et al. Temporary external lumbar drainage for reducing elevated intracranial pressure in HIV-infected patients with cryptococcal meningitis. Int. J. STD AIDS 2008; 19: 268–271.

163

Newton P.N., Thai le H., Tip N.Q. et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin. Infect. Dis. 2002; 35: 769–772.

164

Seaton R.A., Verma N., Naraqi S. et al. The effect of corticosteroids on visual loss in Cryptococcus neoformans var. gattii meningitis. Trans. Roy. Soc. Trop. Med. Hyg. 1997; 91: 50–52.

165

Singh N., Lortholary O., Alexander B.D. et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin. Infect. Dis. 2005; 40: 1756–1761.

166

Ecevit I.Z., Clancy C.J., Schmalfuss I.M., Nguyen M.H. The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy. Clin. Infect. Dis. 2006; 42: 1443–1447.

167

Perfect J.R., Cox G.M., Lee J.Y. et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin. Infect. Dis. 2001; 33: 1824–1833.

168

Patterson T.F., Kirkpatrick W.R., White M. et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group Medicine (Baltimore) 2000; 79: 250–260.

169

Soubani A.O., Chandrasekar P.H. The clinical spectrum of pulmonary aspergillosis. Chest 2002; 121: 1988–1999.

170

Marr K.A., Crippa F., Leisenring W. et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527–1533.

171

Winston D.J., Maziarz R.T., Chandrasekar P.H. et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann. Intern. Med. 2003; 138: 705–713.

172

Ullmann A.J., Lipton J.H., Vesole D.H. et al. Posaconazole or fluconazole for prophylaxis in severe graftversus-host disease. N. Engl. J. Med. 2007; 356: 335–347. American Thoracic Society Documents 125.

173

Cornely O.A., Maertens J., Winston D.J. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 2007; 356: 348–359.

174

van Burik J.A., Ratanatharathorn V., Stepan D.E. et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 2004; 39: 1407–1416.

175

Centers for disease control and prevention. Guidelines for prevention of nosocomial pneumonia. Morbid. Mortal. Wkly Rep. 1997; 46: 1–79.

176

Mennink5Kersten M.A., Verweij P.E. Non-culture-based diagnostics for opportunistic fungi. Infect. Dis. Clin. N. Am. 2006; 20: 711–727.

177

Maertens J., Theunissen K., Verhoef G. et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin. Infect. Dis. 2005; 41: 1242–1250.

178

Hebart H., Klingspor L., Klingebiel T. et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin b in patients after allo-sct. Bone Marrow Transplant. 2009; 43: 553–561.

179

Cordonnier C., Pautas C., Maury S. et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin. Infect. Dis. 2009; 48: 1042–1051.

180

Stevens D.A., Kan V.L., Judson M.A. et al. Practice guidelines for diseases caused by Aspergillus: Infectious Diseases Society of America. Clin. Infect. Dis. 2000; 30: 696–709.

181

Herbrecht R., Denning D.W., Patterson T.F. et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 2002; 347: 408–415.

182

Steinbach W.J., Stevens D.A., Denning D.W., Moss R.B. Advances against aspergillosis. Clin. Infect. Dis. 2003; 37: S155–S156.

183

Wong5Beringer A., Jacobs R.A., Guglielmo B.J. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 1998; 27: 603–618.

184

Graybill J.R., Tollemar J., Torres5Rodriguez J.M. et al. Antifungal compounds: controversies, queries and conclusions. Med. Mycol. 2000; 38: 323–333.

185

Dix S.P., Andriole V.T. Lipid formulations of amphotericin B. Curr. Clin. Top. Infect. Dis. 2000; 20: 1–23.

186

Cornely O.A., Maertens J., Bresnik M. et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (ambiload trial). Clin. Infect. Dis. 2007; 44: 1289–1297.

187

Iwen P.C., Rupp M.E., Langnas A.N. et al. Invasive pulmonary aspergillosis due to aspergillus terreus: 12-year experience and review of the literature. Clin. Infect. Dis. 1998; 26: 1092–1097.

188

Cuenca5Estrella M., Rodriguez5Tudela J.L., Mellado E. et al. Comparison of the in-vitro activity of voriconazole (uk-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J. Antimicrob. Chemother. 1998; 42: 531–533.

189

Clancy C.J., Nguyen M.H. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. 1998; 17: 573–575.

190

Espinel5Ingroff A. In vitro activity of the new triazole voriconazole (uk-109, 496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 1998; 36: 198–202.

191

Espinel5Ingroff A., Boyle K., Sheehan D.J. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001; 150: 101–115.

192

Verweij P.E., Mensink M., Rijs A.J. et al. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J. Antimicrob. Chemother. 1998; 42: 389–392.

193

Sutton D.A., Sanche S.E., Revankar S.G. et al. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J. Clin. Microbiol. 1999; 37: 2343–2345.

194

Cacciapuoti A., Loebenberg D., Corcoran E. et al. In vitro and in vivo activities of sch 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob. Agents Chemother. 2000; 44: 2017–2022.

195

Petraitiene R., Petraitis V., Groll A.H. et al. Antifungal activity and pharmacokinetics of posaconazole (sch 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob. Agents Chemother. 2001; 45: 857–869.

196

Kirkpatrick W.R., McAtee R.K., Fothergill A.W. et al. Efficacy of sch-56592 in a rabbit model of invasive aspergillosis. Antimicrob. Agents Chemother. 2000; 44: 780–782.

197

Oakley K.L., Morrissey G., Denning D.W. Efficacy of sch-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob. Agents Chemother. 1997; 41: 1504–1507.

198

Imai J.K., Singh G., Clemons K.V., Stevens D.A. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob. Agents Chemother. 2004; 48: 4063–4066.

199

Maertens J., Raad I., Petrikkos G. et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 2004; 39: 1563–1571.

200

Maertens J., Glasmacher A., Herbrecht R. et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107: 2888–2897.

201

Lewis R.E., Kontoyiannis D.P. Rationale for combination antifungal therapy. Pharmacotherapy 2001; 21: 149S–164S.

202

Kontoyiannis D.P., Hachem R., Lewis R.E. et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292–299.

203

Sugar A.M. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob. Agents Chemother. 1995; 39: 1907–1912.

204

Popp A.I., White M.H., Quadri T. et al. Amphotericin B with and without itraconazole for invasive aspergillosis: a threeyear retrospective study. Int. J. Infect. Dis. 1999; 3: 157–160.

205

Marr K.A., Boeckh M., Carter R.A. et al. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 2004; 39: 797–802.

206

Stevens D.A., Kullberg B.J., Brummer E. et al. Combined treatment: antifungal drugs with antibodies, cytokines or drugs. Med. Mycol. 2000; 38: 305–315.

207

Nucci M., Pulcheri W., Bacha P.C. et al. Amphotericin B followed by itraconazole in the treatment of disseminated fungal infections in neutropenic patients. Mycoses 1994; 37: 433–437.

208

Roilides E., Pizzo P.A. Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin. Infect. Dis. 1992; 15: 508–524.

209

Latge J.P. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 1999; 12: 310–350.

210

Rowe J.M., Andersen J.W., Mazza J.J. et al. A randomized placebo-controlled phase III study of granulocytemacrophage colony-stimulating factor in adult patients (55 to 70 years of age) with acute myelogenous leukemia: a study of the eastern cooperative oncology group (e1490). Blood 1995; 86: 457–462.

211

Albelda S.M., Talbot G.H., Gerson S.L. et al. Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis: influence of bone marrow recovery in patients with acute leukemia. Am. Rev. Respir. Dis. 1985; 131: 115–120.

212

Groll A., Renz S., Gerein V. et al. Fatal haemoptysis associated with invasive pulmonary aspergillosis treated with highdose amphotericin B and granulocyte-macrophage colonystimulating factor (GM-CSF).Mycoses 1992; 35: 67–75.

213

The international chronic granulomatous disease cooperative study group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N. Engl. J. Med. 1991; 324: 509–516.

214

Denning D.W., Munoz P. Advances in invasive fungal infection and antifungal therapy: introduction. Clin. Microbiol. Infect. 2001; 7: vi.

215

Binder R.E., Faling L.J., Pugatch R.D. et al. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltimore) 1982; 61: 109–124.

216

Saraceno J.L., Phelps D.T., Ferro T.J. et al. Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 1997; 112: 541–548.

217

Caras W.E., Pluss J.L. Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. Mayo Clin. Proc. 1996; 71: 25–30.

218

Caras W.E. Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 1998; 113: 852–853.

219

Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J. Am. Acad. Dermatol. 1990; 23: 607–614.

220

Seaton A., Seaton R.A., Wightman A.J. Management of allergic bronchopulmonary aspergillosis without maintenance oral corticosteroids: a fifteen-year follow-up. Quart. J. Med. 1994; 87: 529–537.

221

Greenberger P.A. Diagnosis and management of allergic bronchopulmonary aspergillosis. Allergy Proc. 1994; 15: 335–339.

222

Behera D., Guleria R., Jindal S.K. et al. Allergic bronchopulmonary aspergillosis: a retrospective study of 35 cases. Indian J. Chest Dis. Allied Sci. 1994; 36: 173–179.

223

Imbeault B., Cormier Y. Usefulness of inhaled high-dose corticosteroids in allergic bronchopulmonary aspergillosis. Chest 1993; 103: 1614–1617.

224

Patterson R., Greenberger P. Allergic bronchopulmonary aspergillosis. Arerugi 1987; 36: 967–969.

225

Laufer P. Assessment of corticosteroid therapy for allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis. J. Asthma 1985; 22: 253–255.

226

Judson M.A., Stevens D.A. Current pharmacotherapy of allergic bronchopulmonary aspergillosis. Expert Opin. Pharmacother. 2001; 2: 1065–1071.

227

Stevens D.A., Moss R.B., Kurup V.P. et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis–state of the art: Cystic Fibrosis Foundation consensus conference. Clin. Infect. Dis. 2003; 37: S225–S264.

228

Stevens D.A., Schwartz H.J., Lee J.Y. et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N. Engl. J. Med. 2000; 342: 756–762.

229

van der Ent C.K., Hoekstra H., Rijkers G.T. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-ige antibody. Thorax 2007; 62: 76–277.

230

Zmeili O.S., Soubani A.O. Pulmonary aspergillosis: a clinical update. Quart. J. Med. 2007; 100: 317–334.

231

Addrizzo5Harris D.J., Harkin T.J., McGuinness G. et al. Pulmonary aspergilloma and AIDS: a comparison of HIVinfected and HIV-negative individuals. Chest 1997; 111: 612–618.

232

Mori T., Ebe T., Isonuma H. et al. Aspergilloma: comparison of treatment methods and prognoses. J. Infect. Chemother 2000; 6: 233–239.

233

Judson M.A., Stevens D.A. The treatment of pulmonary aspergilloma. Curr. Opin. Invest. Drugs 2001; 2: 1375–1377.

234

Kawamura S.,Maesaki S., Tomono K. et al. Clinical evaluation of 61 patients with pulmonary aspergilloma. Intern. Med. 2000; 39: 209–212.

235

Otani Y., Yoshida I., Ohki S. et al. Arterial embolization as preoperative treatment for pulmonary aspergillosis with hemoptysis. Surg. Today 1997; 27: 812–815.

236

Cremaschi P., Nascimbene C., Vitulo P. et al. Therapeutic embolization of bronchial artery: a successful treatment in 209 cases of relapse hemoptysis. Angiology 1993; 44: 295–299.

237

Kato A., Kudo S., Matsumoto K. et al. Bronchial artery embolization for hemoptysis due to benign diseases: immediate and long-term results. Cardiovasc. Intervent. Radiol. 2000; 23: 351–357.

238

Regnard J.F., Icard P., Nicolosi M. et al. Aspergilloma: a series of 89 surgical cases. Ann. Thorac. Surg. 2000; 69: 898–903.

239

Al5Kattan K., Ashour M., Hajjar W. et al. Surgery for pulmonary aspergilloma in post-tuberculous vs. immunocompromised patients. Eur. J. Cardiothorac Surg. 2001; 20: 728–733.

240

Babatasi G., Massetti M., Chapelier A. et al. Surgical treatment of pulmonary aspergilloma: current outcome. J. Thorac. Cardiovasc. Surg. 2000; 119: 906–912.

241

Kaestel M., Meyer W., Mittelmeier H.O., Gebhardt C. Pulmonary aspergilloma: clinical findings and surgical treatment. Thorac. Cardiovasc. Surg. 1999; 47: 340–345.

242

Itoh T., Yamada H., Yamaguchi A. et al. Percutaneous intracavitary antifungals for a patient with pulmonary aspergilloma; with a special reference to in vivo efficacies and in vitro susceptibility results. Intern. Med. 1995; 34: 85–88.

243

Munk P.L., Vellet A.D., Rankin R.N. et al. Intracavitary aspergilloma: transthoracic percutaneous injection of amphotericin gelatin solution. Radiology 1993; 188: 821–823.

244

Klein J.S., Fang K., Chang M.C. Percutaneous transcatheter treatment of an intracavitary aspergilloma. Cardiovasc. Intervent. Radiol. 1993; 16: 321–324.

245

Greenberger P.A. Mold-induced hypersensitivity pneumonitis. Allergy Asthma Proc. 2004; 25: 219–223.

246

Pappas P.G., Rex J.H., Lee J. et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 2003; 37: 634–643.

247

Wisplinghoff H., Bischoff T., Tallent S.M. et al. Nosocomial bloodstream infections in us hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 2004; 39: 309–317.

248

Pappas P.G., Kauffman C.A., Andes D. et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.Clin. Infect. Dis. 2009; 48: 503–535.

249

Ostrosky5Zeichner L., Pappas P.G. Invasive candidiasis in the intensive care unit. Crit. Care Med. 2006; 34: 857–863.

250

Chow J.K., Golan Y., Ruthazer R. et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin. Infect. Dis. 2008; 46: 1206–1213.

251

Rex J.H., Bennett J.E., Sugar A.M. et al. Arandomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia: Candidemia Study Group and the National Institute. N. Engl. J. Med. 1994; 331: 1325–1330.

252

Nguyen M.H., Peacock J.E. Jr, Tanner D.C. et al. Therapeutic approaches in patients with candidemia: evaluation in a multicenter, prospective, observational study. Arch. Intern. Med. 1995; 155: 2429–2435.

253

Anaissie E.J., Vartivarian S.E., Abi5Said D. et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am. J. Med. 1996; 101: 170–176.

254

Kuse E.R., Chetchotisakd P., da Cunha C.A. et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomized double-blind trial. Lancet 2007; 369: 1519–1527.

255

Pappas P.G., Rotstein C.M., Betts R.F. et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 2007; 45: 883–893.

256

Betts R., Glasmacher A., Maertens J. et al. Efficacy of caspofungin against invasive candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006; 106: 466–473.

257

Luzzati R., Amalfitano G., Lazzarini L. et al. Nosocomial candidemia in non-neutropenic patients at an italian tertiary care hospital. Eur. J. Clin. Microbiol. Infect. Dis. 2000; 19: 602–607.

258

Rex J.H., Bennett J.E., Sugar A.M. et al. Intravascular catheter exchange and duration of candidemia: Niaid Mycoses Study Group and the Candidemia Study Group. Clin. Infect. Dis. 1995; 21: 994–996.

259

Nucci M., Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin. Infect. Dis. 2002; 34: 591–599.

260

Walsh T.J., Rex J.H. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin. Infect. Dis. 2002; 34: 600–602.

261

Pappas P.G., Rex J.H., Sobel J.D. et al. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 2004; 38: 161–189.

262

Buchner T., Fegeler W., Bernhardt H. et al. American Thoracic Society Documents 127 Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators. Eur. J. Clin. Microbiol. Infect. Dis. 2002; 21: 337–352.

263

Krishna R., Amuh D., Lowder C.Y. et al. Should all patients with candidaemia have an ophthalmic examination to rule out ocular candidiasis? Eye (Lond) 2000; 14: 30–34.

264

Ostrosky5Zeichner L., Sable C., Sobel J. et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur. J. Clin. Microbiol. Infect. Dis. 2007; 26: 271–276.

265

Schuster M.G., Edwards J.E. Jr, Sobel J.D. et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann. Intern. Med. 2008; 149: 83–90.

266

Masur H., Rosen P.P., Armstrong D. Pulmonary disease caused by Candida species. Am. J. Med. 1977; 63: 914–925.

267

Kontoyiannis D.P., Reddy B.T., Torres H.A. et al. Pulmonary candidiasis in patients with cancer: an autopsy study. Clin. Infect. Dis. 2002; 34: 400–403.

268

Haron E., Vartivarian S., Anaissie E. et al. Primary Candida pneumonia: experience at a large cancer center and review of the literature. Medicine (Baltimore) 1993; 72: 137–142.

269

Cairns M.R., Durack D.T. Fungal pneumonia in the immunocompromised host. Semin. Respir. Infect. 1986; 1: 166–185.

270

Zeluff B.J. Fungal pneumonia in transplant recipients. Semin. Respir. Infect. 1990; 5: 80–89.

271

Edman J.C., Kovacs J.A., Masur H. et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988; 334: 519–522.

272

Bartlett M.S., Queener S.F., Shaw M.M. et al. Pneumocystis carinii is resistant to imidazole antifungal agents. Antimicrob. Agents Chemother. 1994; 38: 1859–1861.

273

Thomas C.F. Jr, Limper A.H. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nature Rev. Microbiol. 2007; 5: 298–308.

274

Thomas C.F. Jr., Limper A.H. Pneumocystis pneumonia. N. Engl. J. Med. 2004; 350: 2487–2498.

275

National Institutes of Health-University of California expert panel for corticosteroids as adjunctive therapy for pneumocystis pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. N. Engl. J. Med. 1990; 323: 1500–1504.

276

Bozzette S.A., Sattler F.R., Chiu J. et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: California Collaborative Treatment Group. N. Engl. J. Med. 1990; 323: 1451–1457.

277

Pareja J.G., Garland R., Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998; 113: 1215–1224.

278

Masur H., Kovacs J.A. Treatment and prophylaxis of Pneumocystis carinii pneumonia. Infect. Dis. Clin. N. Am. 1988; 2: 419–428.

279

Ledergerber B., Mocroft A., Reiss P. et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy: eight European study groups. N. Engl. J. Med. 2001; 344: 168–174.

280

Zellweger C., Opravil M., Bernasconi E. et al. Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study. AIDS 2004; 18: 2047–2053.

281

Yale S.H., Limper A.H. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin. Proc. 1996; 71: 5–13.

282

Sepkowitz K.A. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin. Infect. Dis. 2002; 34: 1098–1107.

283

Sepkowitz K.A., Brown A.E., Telzak E.E. et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. J.A.M.A. 1992; 267: 832–837.

284

Godeau B., Coutant5Perronne V., Le Thi Huong D. et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J. Rheumatol. 1994; 21: 246–251.

285

Velayos F.S., Sandborn W.J. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn’s disease. Inflamm. Bowel. Dis. 2004; 10: 657–660.

286

Hughes W.T., Rivera G.K., Schell M.J. et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N. Engl. J. Med. 1987; 316: 1627–1632.

287

Souza J.P., Boeckh M., Gooley T.A. et al. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin. Infect. Dis. 1999; 29: 1467–1471.

288

Vasconcelles M.J., Bernardo M.V., King C. et al. Aerosolized pentamidine as Pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associatedwith decreased survival and an increased risk of other infections. Biol. Blood Marrow Transplant. 2000; 6: 35–43.

289

Bozzette S.A., Finkelstein D.M., Spector S.A. et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection: Niaid AIDS Clinical Trials Group. N. Engl. J. Med. 1995; 332: 693–699.

290

Langford C.A., Talar5Williams C., Barron K.S., Sneller M.C. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: extended follow-up and rate of relapse. Am. J. Med. 2003; 114: 463–469.

291

Rains B.M. III, Mineck C.W. Treatment of allergic fungal sinusitis with high-dose itraconazole. Am. J. Rhinol. 2003; 17: 1–8.

292

Perfect J.R. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin. Infect. Dis. 2005; 40: S401–S408.

293

Herbrecht R., Letscher5Bru V., Bowden R.A. et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur. J. Clin. Microbiol. Infect. Dis. 2001; 20: 460–466.

294

Larkin J., Montero J.A. Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect. Med. 2003; 20: 210–216.

295

Chamilos G., Lewis R.E., Kontoyiannis D.P. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin. Infect. Dis. 2008; 47: 503–509.

296

Herbrecht R. Posaconazole: a potent, extended-spectrum triazole antifungal for the treatment of serious fungal infections. Int. J. Clin. Pract. 2004; 58: 612–624.

297

van Burik J.A., Hare R.S., Solomon H.F. et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 2006; 42: e61–e65.

298

Walsh T.J., Lutsar I., Driscoll T. et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr. Infect. Dis. J. 2002; 21: 240–248.

299

Raad II, Hachem R.Y., Herbrecht R. et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 2006; 42: 1398–1403.

300

Husain S., Munoz P., Forrest G. et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin. Infect. Dis. 2005; 40: 89–99.

301

Brandt M.E., Warnock D.W. Epidemiology, clinical manifestations, and therapy of infections caused by dematiaceous fungi. J. Chemother. 2003; 15: 36–47.

302

Sharkey P.K., Graybill J.R., Rinaldi M.G. et al. Itraconazole treatment of phaeohyphomycosis. J. Am. Acad. Dermatol. 1990; 23: 577–586.

303

Palaoglu S., Sav A., Basak T. et al. Cerebral phaeohyphomycosis. Neurosurgery 1993; 33: 894–897.

304

Girmenia C., Pagano L., Martino B. et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J. Clin. Microbiol. 2005; 43: 1818–1828.

305

Pappas P.G. Immunotherapy for invasive fungal infections: from bench to bedside. Drug Resist. Updat 2004; 7: 3–10.

The authors declare that there are no conflicts of interest present.